Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis for Refractory Macular Edema in Retinal Vein Occlusion (RAVEN)
NCT01471691Phase 2Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in macular edema, branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), sponsored by Hansoh Pharmaceutical Group. Started Nov 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT01471691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471691.